Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (pvx108) study, which investigates treatment of peanut allergies.

Chiesi Global Rare Diseases has announced the results from its BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug elfabrio at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (elfabrio) is 1 milligram (mg) per kilogram (kg) administered every two weeks.

Sobi and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit patients with c3 glomerulopathy (c3g) and primary immune complex membranoproliferative glomerulonephritis (ic-mpgn).

Clinical-stage biotech company Rallybio corporation has announced that it has received approval from two regulatory bodies for its clinical trial applications (CTAS) for a phase 2 study involving pregnant women.

This month, Verisense have announced that their digital biobank, with data from over one million people, is open for business.

Join us at CPHI Milan 2024, the premier global event for pharmaceutical professionals, from 8-10 October at Fiera Milano, Milan, Italy. Celebrating 35 years of excellence, this event promises unparalleled opportunities for networking, innovation and professional growth. With over 62,000 attendees and 2,500 exhibitors, you’ll experience insightful seminars, cutting-edge exhibitions and new awards such as ‘Woman of the Year’ and ‘Future Leader’.

DermaSensor has announced that the FDA has granted clearance for its real-time, non-invasive skin cancer evaluation system.

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine and diabetes. This is intended to offer resources around disease management, such as access to healthcare providers, tailored support and delivery of selected medications.

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety disorders and three digitally enabled therapies for adult patients with depression for use within the NHS while further data is gathered.

French pharmaceutical company Servier and US-based causal AI and digital twins company Aitia have announced a collaboration to create digital twins as an aid to help treat pancreatic cancer. This collaboration builds on a previous multiple myeloma one that was announced in 2022.

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (hcm).

Finnish company Sooma medical has received breakthrough device designation by the FDA for its portable, at-home neuromodulation device to treat depression.